limbs cause great discomfort for the child, further difficulties in management (especially lifting), and time lost from school. Conventional conservative measures to splint the limb are usually inappropriate, as reduction in joint mobility prevents manipulation of the limb without excessive pain. Here we describe a method for overcoming some of the difficulties in splinting limbs.
Method
By using the "vacuum consolidation" technique1 2 an exact replica of the limb can be made, around which an effective splint can be moulded without causing unnecessary pain. This uses an airtight plastic bag containing Fillite-a very fine particle, the byproduct of ash produced in electricity generating stations. It is fitted with a filtered outlet tube and attached to a vacuum source.3
The child is positioned so that the affected limb lies on a bag of Fillite and this is manoeuvred to produce a mould for the lower half of the limb (see figure) . Evacuation causes the Fillite bag to assume a rigid shape, exactly reproducing the contours of the limb. A second, smaller bag is then placed over the limb completely covering it; evacuation will then complete the mould and the child may be removed by separating the two bags. The remaining negative is an exact replica of the limb, and an accurate reproduction may be produced by using plaster of paris poured into the mould between the two bags. After five to ten minutes of drying only, the vacuum may be released on both bags, allowing the positive cast to be removed and made smooth before it hardens completely.
A splint may now be made by moulding Plastazote around the cast, reinforcing this with longitudinal strips of polypropylene, and this is finished with strips of Velcro. A rough fitting of the splint can be made within two hours of the first impression's being taken.
:. 
Case report
A 48-year-old woman due for an elective cholecystectomy was referred for investigation of recurrent deep vein thromboses occurring over three years. No relatives, apart from her dead mother, had any history of thrombotic disease. The mother had suffered repeated attacks from the age of 48 until her death at 82. The patient was four years postmenopausal and smoked up to 10 cigarettes a day. She was moderately obese, and xanthelasmata were noted.
Laboratory investigations, including routine haematological, coagulation, and liver function tests, gave normal results apart from a fasting plasma triglyceride level of 3-1 mmol/l (274 mg/100 ml) (normal <2-0 mmol/l (177 mg/100 ml) ). The overnight stored plasma showed diffuse lactescence. In view of the history antithrombin III levels were measured by immunodiffusion (Hoechst Partigen) and found to be low (0.7 mg/l compared with the normal range in serum of 2-0-3-5 mg/l). Her blood relations were subsequently tested (see diagram), and seven were found to have low antithrombin III concentrations (0-7-1 0 mg/l). Only the patient's elder daughter had a raised fasting triglyceride level of 3 0 mmol/l (266 mg/100 ml) as well as a low antithrombin concentration.
The patient was advised to give up smoking and take a low calorie diet. She was anticoagulated with warfarin uneventfully for six months. The dose was reduced preoperatively and a prophylactic dextran infusion was given during the cholecystectomy. Intermittent claudication is the commonest symptom of an increasingly common disorder: obliterative arterial disease affecting the legs. Hitherto, despite the wide pharmaceutical range offered, there has been little medical treatment of proved value to prescribe and, in particular, vasodilator drugs have proved disappointing. This paper describes a double-blind controlled trial of naftidrofuryl (Praxilene), a new drug that is believed to facilitate oxygen exchange and enhance metabolism in ischaemic tissues.
Patients, methods, and results
Consecutive patients attending a peripheral vascular clinic with stable claudication were included. Once informed consent had been obtained the patient was issued with capsules in a coded container, maintaining a doubleblind design. The treatment group received naftidrofuryl 100 mg thrice daily for three months; the controls received an inert placebo capsule of identical appearance. Assessment was based both on subjective and objective criteria. The patient was asked to take regular exercise and to note any improvement or deterioration. No specific instructions on smoking or diet were given during the period of observation. Clinical severity was defined according to the reported onset of claudication at normal walking pace on the level: less than 100 yards-severe; 
Comment
The tendency for symptoms of claudication to improve during a period of observation is well known to those interested in vascular disease and probably accounts for the gross overprescribing of vasodilator or "vasoactive" drugs. This improvement occurred despite the fact that patients with apparently stable claudication were studied and that specific instructions on diet and smoking were withheld. In effect, by observing their own symptoms regularly, the patients were undertaking a programme of exercise similar to that commonly recommended for the condition.
We have been unable to show a benefit in our patients with claudication from oral naftidrofuryl. The administration of naftidrofuryl in more advanced vascular disease and by alternative routes may have different effects and requires separate study.
